Fig. 2: The expression level of CRABP2 is related to the sensitivity of ovarian cancer cells to chemotherapy drugs.
From: CRABP2 affects chemotherapy resistance of ovarian cancer by regulating the expression of HIF1α
A The relationship between the expression level of CRABP2 and the sensitivity of patients to chemotherapy. B IC50 value of cisplatin in ovarian cancer cells of ascites was determined. C, The CRABP2 expression levels of ovarian cancer cells of ascites. D The relationship of CRABP2 expression levels and IC50 values of cisplatin in ovarian cancer cells of ascites. E IC50 values of cisplatin in ovarian cancer resistant cells and parental cells. F The CRABP2 expression levels of ovarian cancer resistant cells and parental cells. G, Cell lines overexpressing CRABP2 were constructed in ovarian cancer parental cells. H IC50 values of cisplatin in CRABP2 overexpressing and control cells. I and J, The cell death induced by 10 μM DDP in control cells and overexpressed CRABP2 cells of A2780 (I) and SKOV3 (J) for 48 h was detected by flow cytometry. K CRABP2 knockdown cell lines were constructed in drug-resistant ovarian cancer cells. L IC50 values of cisplatin in CRABP2 knockdown and control cells. M and N The cell death induced by 50 μM DDP in control and CRABP2 knockdown cells of A2780/DDP (M) and SKOV3/DDP (N) for 48 h.
